Opinion

Video

Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

Author(s):

Gregory W. Roloff, MD,Jae Park, MD

Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.

Related Videos
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Minoo Battiwalla, MD, MS
Related Content
Courtney DiNardo, MD, MSCE, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 28th 2024

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Alex F. Herrera, MD
October 25th 2024

Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Paula G. O’Connor, MD, chief medical officer, Nurix Therapeutics
October 22nd 2024

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

Jorge Cortes, MD, of Georgia Cancer Center
October 21st 2024

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research